Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2024
This study will compare the effects of Quizartinib versus placebo in combination with chemotherapy in participants with newly diagnosed FMS-like tyrosine kinase 3 (FLT3)-internal tandem duplication (ITD) negative acute myeloid leukemia (AML).
Epistemonikos ID: 72ea906e195c9318c36098eaf87fc88169221e31
First added on: Sep 01, 2024